Biocept's Blood-based Liquid Biopsy for Non-small Cell Lung Carcinoma Highlighted in American Society of Clinical Oncology (ASCO) Abstract
Clinical utility and clinical validation of CTCs and ctDNA to analyze cancer biomarkers ALK, ROS1 and EGFR demonstrated
The abstract demonstrates the clinical utility of a liquid biopsy using Biocept's technology, not only for a patient where there is insufficient tissue from a biopsy, but also in order to better represent a patient's biomarker status by avoiding challenges associated with tissue heterogeneity, all accomplished with a simple blood draw.
"By providing oncologists such as myself with genomic testing results
performed on a simple blood test, we are able to stratify patients based
on biomarker status in real-time, which has the potential to drastically
change how patients with solid cancers such as non-small cell lung
cancers (NSCLC) are monitored," stated Dr.
"The ease of real-time monitoring and early identification
of the emergence of resistance reduces the time to make a treatment
change, which in a setting of metastatic cancer, is crucial.
Additionally, the health economic benefit of obtaining actionable
biomarker status from a simple blood draw in lieu of a surgical
procedure is an added advantage to our health care system," stated
The abstract also highlights the
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which they
are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of these
words or other variations on these words or comparable terminology. To
the extent that statements in this release are not strictly historical,
including without limitation statements as to improvement of outcomes,
our impact on diagnostic strategies and planned future offerings, such
statements are forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. The
reader is cautioned not to put undue reliance on these forward-looking
statements, as these statements are subject to numerous risk factors as
set forth in our
View source version on businesswire.com: http://www.businesswire.com/news/home/20150528005339/en/
Investor Contact:
LHA
jcain@lhai.com
310-691-7100
Source:
News Provided by Acquire Media